Bio Developments

Pic:getty/kotofeja

AC Immune acquires Parkinson’s vaccine candidate

By Rachel Arthur

AC Immune will acquire Affiris’ portfolio of therapeutics targeting alpha-synuclein (a-syn), which includes a vaccine candidate for the treatment of Parkinson’s disease.

© GettyImages/koto_feja

Dispatches from Bio Digital 2021

Mogrify looks to transform cell therapy development

By Jane Byrne

Biotech, Mogrify, recently closed a Series A financing of US$17m, bringing the total raised to US$33m in the round, with the investment set to support the advancement of the company’s immuno-oncology and ophthalmology programs.

© GettyImages/Design Cells

4D Pharma expanding clinical data in multiple indications

By Jane Byrne

Live biotherapeutic product (LBP) developer, 4D Pharma, says it is building a ‘strong body of evidence’ for its portfolio of bacterial strains in relation to cancer, asthma, and neurodegenerative diseases, while the company also calls its recent dual...

© GettyImages/Urupong

Dispatches from Bio Digital 2021

Pfizer CEO: ‘There is renewed hope and trust in science’

By Jane Byrne

A lesson learnt from the COVID-19 pandemic was that human ingenuity prevailed and resolved an issue that challenged the world; the crisis also reinforced faith in the power of science, said Dr Albert Bourla, CEO of Pfizer, in a keynote interview during...